Does the media refer more to STIM or KIDS?

In the previous week, Neuronetics had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Neuronetics and 4 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.06 beat Neuronetics' score of 0.62 indicating that OrthoPediatrics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OrthoPediatrics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to STIM or CLPT?

In the previous week, Neuronetics had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.85 beat Neuronetics' score of 0.62 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ClearPoint Neuro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STIM or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to Neuronetics' net margin of -24.48%. Delcath Systems' return on equity of 0.51% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -24.48% -139.83% -27.13% Delcath Systems 0.62% 0.51% 0.46%

Does the media prefer STIM or DCTH?

In the previous week, Neuronetics had 4 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.94 beat Neuronetics' score of 0.62 indicating that Delcath Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer STIM or SI?

In the previous week, Neuronetics had 4 more articles in the media than Shoulder Innovations. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for Shoulder Innovations. Shoulder Innovations' average media sentiment score of 1.00 beat Neuronetics' score of 0.62 indicating that Shoulder Innovations is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shoulder Innovations 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CV or STIM more profitable?

Neuronetics has a net margin of -24.48% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets CapsoVision -198.87% N/A -136.03% Neuronetics -24.48% -139.83% -27.13%

Neuronetics (STIM) Competitors

$1.73 -0.15 (-7.98%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.72 0.00 (-0.29%)

As of 07/24/2026 07:34 PM Eastern

Compare

STIM vs. KIDS, CLPT, DCTH, SI, and CV

Should you buy Neuronetics stock or one of its competitors? MarketBeat compares Neuronetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neuronetics include OrthoPediatrics (KIDS), ClearPoint Neuro (CLPT), Delcath Systems (DCTH), Shoulder Innovations (SI), and CapsoVision (CV). These companies are all part of the "medical equipment" industry.

How does Neuronetics compare to OrthoPediatrics?

Neuronetics (NASDAQ:STIM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Neuronetics presently has a consensus price target of $4.00, suggesting a potential upside of 131.21%. OrthoPediatrics has a consensus price target of $24.78, suggesting a potential upside of 31.31%. Given Neuronetics' higher possible upside, equities analysts plainly believe Neuronetics is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Neuronetics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

Neuronetics has higher earnings, but lower revenue than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.81	-$39M	-$0.54	N/A
OrthoPediatrics	$236.35M	2.05	-$39.65M	-$1.68	N/A

OrthoPediatrics has a net margin of -16.31% compared to Neuronetics' net margin of -24.48%. OrthoPediatrics' return on equity of -7.01% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Neuronetics had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Neuronetics and 4 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 1.06 beat Neuronetics' score of 0.62 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OrthoPediatrics beats Neuronetics on 10 of the 16 factors compared between the two stocks.

How does Neuronetics compare to ClearPoint Neuro?

Neuronetics (NASDAQ:STIM) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

Neuronetics has a net margin of -24.48% compared to ClearPoint Neuro's net margin of -71.57%. Neuronetics' return on equity of -139.83% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

In the previous week, Neuronetics had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.85 beat Neuronetics' score of 0.62 indicating that ClearPoint Neuro is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ClearPoint Neuro has lower revenue, but higher earnings than Neuronetics. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.81	-$39M	-$0.54	N/A
ClearPoint Neuro	$40.61M	10.43	-$25.54M	-$1.01	N/A

Neuronetics currently has a consensus target price of $4.00, suggesting a potential upside of 131.21%. ClearPoint Neuro has a consensus target price of $23.00, suggesting a potential upside of 62.89%. Given Neuronetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neuronetics is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Neuronetics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Summary

Neuronetics beats ClearPoint Neuro on 12 of the 16 factors compared between the two stocks.

How does Neuronetics compare to Delcath Systems?

Neuronetics (NASDAQ:STIM) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

In the previous week, Neuronetics had 4 more articles in the media than Delcath Systems. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.94 beat Neuronetics' score of 0.62 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 8.4% of Neuronetics shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Neuronetics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Neuronetics currently has a consensus price target of $4.00, suggesting a potential upside of 131.21%. Delcath Systems has a consensus price target of $22.17, suggesting a potential upside of 81.40%. Given Neuronetics' higher probable upside, research analysts clearly believe Neuronetics is more favorable than Delcath Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Delcath Systems	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Delcath Systems has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.81	-$39M	-$0.54	N/A
Delcath Systems	$90.44M	4.66	$2.70M	$0.01	1,222.00

Delcath Systems has a net margin of 0.62% compared to Neuronetics' net margin of -24.48%. Delcath Systems' return on equity of 0.51% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Delcath Systems beats Neuronetics on 12 of the 16 factors compared between the two stocks.

How does Neuronetics compare to Shoulder Innovations?

Neuronetics (NASDAQ:STIM) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Neuronetics has higher revenue and earnings than Shoulder Innovations. Neuronetics is trading at a lower price-to-earnings ratio than Shoulder Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.81	-$39M	-$0.54	N/A
Shoulder Innovations	$47.32M	8.95	-$40.36M	-$166.96	N/A

Neuronetics has a net margin of -24.48% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

In the previous week, Neuronetics had 4 more articles in the media than Shoulder Innovations. MarketBeat recorded 6 mentions for Neuronetics and 2 mentions for Shoulder Innovations. Shoulder Innovations' average media sentiment score of 1.00 beat Neuronetics' score of 0.62 indicating that Shoulder Innovations is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shoulder Innovations	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neuronetics currently has a consensus target price of $4.00, suggesting a potential upside of 131.21%. Shoulder Innovations has a consensus target price of $21.00, suggesting a potential upside of 2.84%. Given Neuronetics' higher probable upside, research analysts clearly believe Neuronetics is more favorable than Shoulder Innovations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 29.0% of Shoulder Innovations shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Shoulder Innovations beats Neuronetics on 8 of the 15 factors compared between the two stocks.

How does Neuronetics compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Neuronetics (NASDAQ:STIM) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

CapsoVision has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	23.93	-$25.32M	-$2.34	N/A
Neuronetics	$149.16M	0.81	-$39M	-$0.54	N/A

CapsoVision currently has a consensus price target of $8.50, suggesting a potential upside of 30.97%. Neuronetics has a consensus price target of $4.00, suggesting a potential upside of 131.21%. Given Neuronetics' higher possible upside, analysts clearly believe Neuronetics is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.6% of Neuronetics shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 8.4% of Neuronetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Neuronetics has a net margin of -24.48% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-198.87%	N/A	-136.03%
Neuronetics	-24.48%	-139.83%	-27.13%

In the previous week, Neuronetics had 5 more articles in the media than CapsoVision. MarketBeat recorded 6 mentions for Neuronetics and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.89 beat Neuronetics' score of 0.62 indicating that CapsoVision is being referred to more favorably in the media.

Company	Overall Sentiment
CapsoVision	Very Positive
Neuronetics	Positive

Summary

Neuronetics beats CapsoVision on 9 of the 15 factors compared between the two stocks.

Get Neuronetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STIM vs. The Competition

Export

Metric	Neuronetics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$130.82M	$7.29B	$6.87B	$12.26B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	-3.20	48.63	27.14	23.64
Price / Sales	0.81	96.87	517.06	88.99
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	4.55	6.73	10.28	6.07
Net Income	-$39M	$162.27M	$3.60B	$331.99M
7 Day Performance	6.79%	-5.05%	-1.27%	-0.63%
1 Month Performance	36.22%	-5.86%	-0.37%	-2.00%
1 Year Performance	-61.47%	-2.88%	18.30%	13.62%

Neuronetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STIM Neuronetics	3.5512 of 5 stars	$1.73 -8.0%	$4.00 +131.2%	-61.1%	$130.82M	$149.16M	N/A	180	Analyst Forecast
KIDS OrthoPediatrics	3.0755 of 5 stars	$19.42 -0.5%	$24.78 +27.6%	-17.1%	$499.70M	$243.30M	N/A	200
CLPT ClearPoint Neuro	2.7618 of 5 stars	$15.27 +1.5%	$23.00 +50.6%	+25.2%	$456.72M	$36.97M	N/A	110	News Coverage
DCTH Delcath Systems	2.702 of 5 stars	$12.75 +1.3%	$22.17 +73.9%	+7.2%	$440.13M	$85.23M	1,275.00	60	News Coverage
SI Shoulder Innovations	1.644 of 5 stars	$20.42 -2.7%	$21.00 +2.9%	N/A	$423.41M	$47.32M	N/A	61

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STIM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neuronetics (STIM) Competitors

STIM vs. KIDS, CLPT, DCTH, SI, and CV

How does Neuronetics compare to OrthoPediatrics?

Summary

How does Neuronetics compare to ClearPoint Neuro?

Summary

How does Neuronetics compare to Delcath Systems?

Summary

How does Neuronetics compare to Shoulder Innovations?

Summary

How does Neuronetics compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neuronetics (STIM) Competitors

STIM vs. KIDS, CLPT, DCTH, SI, and CV

How does Neuronetics compare to OrthoPediatrics?

Do analysts recommend STIM or KIDS?

Which has more risk & volatility, STIM or KIDS?

Which has better valuation and earnings, STIM or KIDS?

Is STIM or KIDS more profitable?

Do institutionals and insiders hold more shares of STIM or KIDS?

Does the media refer more to STIM or KIDS?

Summary

How does Neuronetics compare to ClearPoint Neuro?

Is STIM or CLPT more profitable?

Does the media refer more to STIM or CLPT?

Do insiders and institutionals hold more shares of STIM or CLPT?

Which has higher earnings & valuation, STIM or CLPT?

Do analysts recommend STIM or CLPT?

Which has more risk and volatility, STIM or CLPT?

Summary

How does Neuronetics compare to Delcath Systems?

Does the media prefer STIM or DCTH?

Do insiders & institutionals hold more shares of STIM or DCTH?

Which has more volatility and risk, STIM or DCTH?

Do analysts prefer STIM or DCTH?

Which has preferable valuation & earnings, STIM or DCTH?

Is STIM or DCTH more profitable?

Summary

How does Neuronetics compare to Shoulder Innovations?

Which has preferable earnings & valuation, STIM or SI?

Is STIM or SI more profitable?

Does the media prefer STIM or SI?

Do analysts rate STIM or SI?

Do insiders and institutionals hold more shares of STIM or SI?

Summary

How does Neuronetics compare to CapsoVision?

Which has better valuation and earnings, CV or STIM?

Do analysts prefer CV or STIM?

Do institutionals & insiders hold more shares of CV or STIM?

Is CV or STIM more profitable?

Does the media prefer CV or STIM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STIM vs. The Competition

Neuronetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools